Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Sara Hurvitz, M.D.
Sara Hurvitz, M.D.


Internal Medicine

General Information:



Assistant Clinical Professor, Department of Medicine, Hematology/Oncology
Director, Hematology/Oncology Breast Cancer Program
Co-Director, Santa Monica-UCLA Outpatient Hematology/Oncology Practice
Medical Director, JCCC Clinical Research Unit
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

UCLA Medical Center, Santa Monica
Ronald Reagan UCLA Medical Center
Saint John's Health Center


Hematology/Oncology, UCLA School of Medicine, 2003 - 2006
Chief Resident, Internal Medicine, UCLA School of Medicine, 2002 - 2003
Internal Medicine, UCLA School of Medicine, 2000 - 2002
Internal Medicine, UCLA School of Medicine, 1999 - 2000
Medical Degree:
M.D., USC School of Medicine, 1999


Board Certification(s):
Internal Medicine, American Board of Internal Medicine, 2002
Medical Oncology, American Board of Internal Medicine, 2006
Hematology, American Board of Internal Medicine, 2006

Contact Information:

(310) 829-5471 or (888) 662-8252 [(888) ONC-UCLA] Information and patient appointments

Practice Information:

Clinical Interest(s):

Scientific Interest(s):

Dr. Sara Hurvitz is interested in designing and implementing phase I and II (translational) breast cancer clinical trials. She is particularly interested in the development and testing of new targeted therapies for the treatment of breast cancer.

Dr. Hurvitz is also interested in studying the gene expression patterns in a variety of breast cancer populations, and evaluating these patterns to detect new subtypes of breast cancer that may be more accurately targeted by novel therapies.

Selected Cancer-Related Publications:

Hurvitz SA, Hu Y, O'Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 2013 May;39(3):219-29. Epub 2012 May 31

Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey JR, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson CI, Brufsky AM, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM, Mackey J, Falkson C, Brufsky A. Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012 Jun 15;18(12):3478-86. Epub 2012 Apr 13

Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11

Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010 Dec 1;28(34):5110-5. Epub 2010 Oct 25

Hurvitz SA, Finn RS. What's positive about 'triple-negative' breast cancer? Future Oncol. 2009 Sep;5(7):1015-25.